싱귤레이트 (CING) 주가

싱귤레이트(CING)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $5.22 (+1.36%), 시가총액 $0.06B, 52주 최저~최고 $3.33 ~ $11.66.

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

핵심 지표

• 현재가: $5.22 (+1.36%)
• 시가총액: $0.06B
• 52주 최저~최고: $3.33 ~ $11.66
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

싱귤레이트의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

싱귤레이트 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.25

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 25.73
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문